1
Toufike Kanouni
Qing Dong, Toufike Kanouni, Michael B Wallace: MAPK/ERK kinase inhibitors. Takeda Pharmaceutical Company, David M Stemerick, Mitchell R Brustein, September 20, 2011: US08022057 (1 worldwide citation)

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


2
Toufike Kanouni
Qing Dong, Toufike Kanouni, John David Lawson, Michael B Wallace: Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK. Takeda Pharmaceutical Company, Matthew J Russo, David M Stemerick, April 16, 2013: US08420816

Disclosed are JAK inhibitors of formula I where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the ...


3
Toufike Kanouni
Qing Dong, Xianchang Gong, Stephen W Kaldor, Toufike Kanouni, Nicholas Scorah, Michael B Wallace, Feng Zhou: MAPK/ERK KINASE INHIBITORS. TAKEDA PHARMACEUTICAL COMPANY, TAKEDA SAN DIEGO, May 27, 2010: US20100130518-A1

Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of usin ...


4
Toufike Kanouni
Qing Dong, Toufike Kanouni, John David Lawson, Michael B Wallace: Dihydropyrrolonaphtyridinone compounds as inhibitors of jak. Takeda Pharmaceutical Company, June 9, 2011: US20110136780-A1

Disclosed are JAK inhibitors of formula I where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the ...


5
Toufike Kanouni
MarK Adams, Qing Dong, Toufike Kanouni, Stephen W Kaldor, Nicholas Scorah, Michael B Wallace: Mapk/erk kinase inhibitors. Takeda Pharmaceutical Company, Takeda San Diego, May 14, 2009: US20090124595-A1

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


6
Terauchi Jun, Kuno Haruhiko, Nara Hiroshi, Oki Hideyuki, Sato Kenjiro: Heterocyclic amide compound and use thereof as an mmp-13 inhibitor. Takeda Pharmaceutical Company, Terauchi Jun, Kuno Haruhiko, Nara Hiroshi, Oki Hideyuki, Sato Kenjiro, TAKASHIMA Hajime, November 10, 2005: WO/2005/105760 (67 worldwide citation)

The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen-containing heterocycle, ring B is an optionall ...


7
Cho Nobuo, Kasai Shizuo, Yamashita Toshiro: (Ja) 糖尿病の予防・治療剤, (En) Prophylactic/therapeutic agent for diabetes. Takeda Pharmaceutical Company, Cho Nobuo, Kasai Shizuo, Yamashita Toshiro, TAKASHIMA Hajime, October 5, 2006: WO/2006/104280 (57 worldwide citation)

(EN) A 11&bgr;-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1) or a salt thereof or a prodrug of the compound or salt. The inhibitor has an excellent activity and is useful as a prophylactic/therapeutic agent for diabetes, insulin resistance, obesity, a ...


8
Yoshinari Tomohiro, Uchiyama Yoshihiro: (Ja) シームレスカプセル, (En) Sealmess capsule. Takeda Pharmaceutical Company, Yoshinari Tomohiro, Uchiyama Yoshihiro, TAKASHIMA Hajime, January 8, 2009: WO/2009/004999 (48 worldwide citation)

(EN) Disclosed is a seamless capsule which can be produced without using any interfacial tension regulator or gelation accelerator. Specifically disclosed is a seamless capsule comprising: a shell formed by a shell composition comprising a gelatin and a plasticizer and containing no interfacial tens ...


9
Oi Satoru, Maezaki Hironobu, Suzuki Nobuhiro: Pyridine compounds as inhibitors of dipeptidyl peptidase iv. Takeda Pharmaceutical Company, Oi Satoru, Maezaki Hironobu, Suzuki Nobuhiro, TAKASHIMA Hajime, May 12, 2005: WO/2005/042488 (46 worldwide citation)

A compound represented by the formula wherein R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; R3 is an optionally substituted aromatic group; R4 is an optionally substituted amino group; L is a divalent chain hyd ...


10
Feng Jun, Gwaltney Stephen L, Stafford Jeffrey A, Zhang Zhiyuan, Elder Bruce, Isbester Paul, Palmer Grant, Ulysse Luckner, Salsbury Jonathon: Dipeptidyl peptidase inhibitors. Takeda Pharmaceutical Company, Feng Jun, Gwaltney Stephen L, Stafford Jeffrey A, Zhang Zhiyuan, Elder Bruce, Isbester Paul, Palmer Grant, Ulysse Luckner, Salsbury Jonathon, WEITZ David J, October 13, 2005: WO/2005/095381 (45 worldwide citation)

Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising Formula (I): ##STR1## wherein M is N or CR4; Q1 and Q2 are each independently selected from the group consisting of CO, SO, SO2, and C=NR9; and eac ...